John Cumbers

For an aging asset headed off patent, a better linker system = a compelling next-gen version of that drug. Ridge already has partnerships signed across pharma, biotech, and industrial players. Full article available here: synbiobeta.com/read/kightling…

So what does Ridge build? Weston: "I don't believe models alone are an enduring moat, data and products are." One wet lab + purpose-built ML, generating millions of data points in days to fuel the models. Three product lines come out of that engine: ➤ NativeLink: enzymes that precisely attach drug payloads to antibodies, fixing the inconsistent conjugation that drives ADC toxicity ➤ ProTrigger: linkers that keep a drug inert until it hits diseased tissue instead of activating along the way ➤ Catalytic Medicines: engineered enzymes that ARE the therapeutic, performing a reaction on the target instead of just binding to it

Huge congrats to @WKightlinger, CEO of Ridge Biotechnologies, on winning the Rising Star Award at @SynBioBeta 2026. Our editor @AaronBlotnick sat down with Weston for an exclusive interview. Here's what Ridge is building 🧵

How do you get four fierce pharma competitors to co-found a company together? In 2020, @pfizer, @AstraZeneca, @Merck, and @tevapharm did exactly that, with the goal of exploring AI 3 years before @OpenAI's @ChatGPTapp existed. Here's the story behind @AionLabs, and why its own leadership says it couldn't happen today 🧵

@m_goes_distance I think you would love out @SynBioBeta conference. We cover many of these topics every year.

biotech ideas we're funding rn: - Stripe for gene therapies. - GitHub for wet labs. - Cloudflare for clinical trials. - Plaid for biomarkers. - Bloomberg for biological age. - Costco for GMP manufacturing. - Anduril for biosecurity. - NVIDIA for programmable biology. - Cursor for molecular biology. - A "WHOOP for cells," not steps. If infrastructure precedes the science, biotech accelerates 10x faster if youre backing this wave, i'd love to chat.

@NikoMcCarty Amazing! @AaronBlotnick, @SynBioBeta, and myself will be visiting in the coming weeks as well.

A Reading Guide to Chinese Biotech Some friends and I visited China to learn about its biotech ecosystem. Beforehand, we assembled a list of 51 "high signal" books, podcasts, and articles to help us prepare. During the trip, we also asked people who *they* followed for their news on China, and then we added many of those names to this guide. Hopefully this will be a useful resource for folks who are planning to visit (which I recommend, especially if you work in drug development.)

If you have questions you would like answered about the China Bioecononomy, please share them with our correspondent @AaronBlotnick as @SynBioBeta travels to China in the coming weeks.

SynBioBeta 2027 Super Early Bird pricing is available through Friday, June 15. Join the AIxBio founders, biopharma leaders, investors, and startups building the future of biology. Presenting sponsor: Pumpkinseed May 3–6, 2027 | San Jose, CA Lock in your pass early. syntheticbiologysummit.com/2027/early-bird

Four investment firms think they've found where the missing 20% of critical mineral supply is hiding. The answer: biology. A new white paper lays out the case 🧵

Our writer Mohamed Soufi has the full profile on @SynBioBeta: synbiobeta.com/read/why-flies… Need a hard-to-manufacture protein expressed? Reach out to Matt to learn if the EntoEngine is right for you: matt@futurefields.io

E. coli, CHO, and yeast have had 50 years of development. Future Fields has had six, and has already expressed around 50 proteins. Matt says the hard problems are largely solved. What's left is which of the millions of possible proteins they're best positioned to go after.

CEO @M_AndersonBaron frames the target simply: the complexity of a CHO system at the cost of E. coli. My favorite part is the origin. Matt and co-founder (and wife) @jalenetayler came up with this in a @TimHortons line in 2018, trying to make growth factors for a cultivated chicken nugget cheaply enough to matter. Nugget → growth factor problem → fly. 🪰

The economics follow. Seven months from sequence to scaled process, vs 18-24. Every protein runs on the same infrastructure instead of a fresh round of bioreactor optimization. Strains stay genetically stable. Biomass can be frozen and stockpiled ahead of a run.

E. coli and yeast can't fold complex proteins. CHO can, but it's one cell type in a tank. Future Fields can target expression to specific fly cell types, opening up proteins that are hard or impossible to make any other way.

Future Fields uses Drosophila melanogaster to express proteins that legacy systems can't. The reason it works isn't the fly. It's that a whole organism gives you a toolbox of specialized cell types to produce in.

A bioreactor grows one type of cell. A fruit fly grows more than 200 at once. That's the whole bet behind @futurefieldsHQ , and it's a better one than "insects are cheap." 🧵🪰

🧬 Week 28, 2026: 13 Bay Area bio-economy events. 🧵👇

Are therapeutics startups the crabs of the biotech world? In evolutionary biology, there's a phenomenon called carcinization, where different species, again and again, independently evolve into something that looks like a crab. It's happened at least 5 times. 🧵 (11)

Probably the most important presentation at #BIO2026